martes, 8 de agosto de 2017

Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)—Health Professional Version - National Cancer Institute

National Cancer Institute

Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version



SECTIONS





Changes to This Summary (08/03/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text about a review of patients treated on the LMB-89, LMB-96, and LMB-2001 trials that identified 67 of 1,322 patients who relapsed and the reported factors that were associated with better survival.
Added Meyer et al. as reference 8.
Added text about the APEC1621 (NCT03155620) trial as a treatment option under clinical evaluation for lymphoblastic lymphoma.
Added text about the APEC1621 (NCT03155620) trial as a treatment option under clinical evaluation for anaplastic large cell lymphoma.
Revised text about the genetic alterations that are observed in pediatric-type follicular lymphoma (cited Louissaint et al. and Schmidt et al. as references 13 and 14, respectively).
Added Maciejka-Kemblowska et al. as reference 30.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
  • Updated: August 3, 2017

No hay comentarios:

Publicar un comentario